1. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.
- Author
-
Lin, Rick, Anderson, Anthony, Natori, Yoichiro, Raja, Mohammed, Morris, Michele, Jimenez, Antonio, Beitinjaneh, Amer, Wang, Trent, Goodman, Mark, Lekakis, Lazaros, Spiegel, Jay, Holtzman, Noa, Pereira, Denise, Benjamin, Cara, Natori, Akina, Komanduri, Krishna, and Camargo, Jose
- Subjects
Humans ,Cytomegalovirus Infections ,Male ,Virus Activation ,Middle Aged ,Female ,Cytomegalovirus ,Incidence ,Immunotherapy ,Adoptive ,Adult ,Receptors ,Chimeric Antigen ,Aged - Abstract
Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19 days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P = .01), and those who received corticosteroids (39 vs 21%; P = .03), anakinra (56 vs 28%; P = .02), or ≥2 immunosuppressants (41 vs 21%; P = .02). Receipt of corticosteroids (18 vs 0%; P = .004), tocilizumab (14 vs 0%; P = .04), anakinra (33 vs 7%; P = .008), and ≥2 immunosuppressants (20 vs 0%; P = .001) were all associated with cs-CMV. Receiving ≥2 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P = .03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P = .001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.
- Published
- 2024